Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07631299 · ClinicalTrials.gov registry record · Early Phase 1
Nebulized AER101 in Pre-op NSCLC
A Early Phase 1 study, sponsored by University of Oklahoma.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT07631299 is a Early Phase 1 study that has not yet begun recruiting, run by University of Oklahoma. The registered enrollment target is 5 participants.
The verdict
NCT07631299, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Oklahoma.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective of this pilot study is to determine if AER101 can decrease glycolysis in non-small cell lung cancer (NSCLC). Glycolysis is the process cells use to break down sugar (glucose) into a smaller substance in the fluid part inside the cell. Many lung cancers begin in bronchi, bronchioles and alveoli cells surrounding the airways, which enables nebulization to deposit AER101 on lung tumors. Participants in the study will self-administer AER101 via a hand-held personal nebulizer three times per day (dosing at least 4 hours apart) for 14 days prior to undergoing surgery for lung cancer.
Interventions
- DRUG AER101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07631299
The ClinicalTrials.gov registry entry for NCT07631299 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AER101 is the first listed.
NCT07631299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07631299 about?
NCT07631299 is a clinical study titled "Nebulized AER101 in Pre-op NSCLC". The primary objective of this pilot study is to determine if AER101 can decrease glycolysis in non-small cell lung cancer (NSCLC). Glycolysis is the process cells use to break down sugar (glucose) into a smaller substance in the fluid part inside the cell. Many lung cancers begin in bronchi, bronchi...
What is the current status of trial NCT07631299?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2026-06. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07631299?
The interventions under investigation include: AER101 (DRUG).
Who is sponsoring clinical trial NCT07631299?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.